Clinical Trial

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

Study acronym: ENERGIZE-T
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
Protocol Amendment History 51 amendments
This ClinicalTrials.gov record has been amended 51 times since 2021-02-22; most recent amendment 2026-06-19.
Status change: Recruiting → Active, Not Recruiting 2023-05-19
Status change: Not Yet Recruiting → Recruiting 2021-10-08
Trial Details
NCT Number NCT04770779
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Enrollment 258 participants
Start Date 2021-11-30
Primary Completion 2024-04-11 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-31